Format

Send to

Choose Destination
J Allergy Clin Immunol. 2016 Oct;138(4):1051-1059. doi: 10.1016/j.jaci.2016.02.027. Epub 2016 Apr 7.

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.

Author information

1
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
2
Novartis Pharmaceuticals, East Hanover, and Novartis Pharma AG, Basel, Switzerland.
3
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec, Canada.
4
Departments of Medicine and Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.
5
Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
6
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
7
Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
8
Karolinska Institutet, Department of Medicine, Karolinska University, Stockholm, Sweden.
9
Novartis Pharmaceuticals, East Hanover, NJ.
10
Novartis Pharmaceuticals, East Hanover, and Novartis Pharma AG, Basel, Switzerland. Electronic address: anton.drollmann@novartis.com.

Abstract

BACKGROUND:

Omalizumab is an established anti-IgE therapy for the treatment of allergic diseases that prevents IgE from binding to its receptor. QGE031 is an investigational anti-IgE antibody that binds IgE with higher affinity than omalizumab.

OBJECTIVE:

This study compared the effects of QGE031 with those of omalizumab on clinical efficacy, IgE levels, and FcεRI expression in a clinical model of allergic asthma.

METHODS:

Thirty-seven patients with mild allergic asthma were randomized to subcutaneous omalizumab, placebo, or QGE031 at 24, 72, or 240 mg every 2 weeks for 10 weeks in a double-blind, parallel-group multicenter study. Inhaled allergen challenges and skin tests were conducted before dosing and at weeks 6, 12, and 18, and blood was collected until 24 weeks after the first dose.

RESULTS:

QGE031 elicited a concentration- and time-dependent change in the provocative concentration of allergen causing a 15% decrease in FEV1 (allergen PC15) that was maximal and approximately 3-fold greater than that of omalizumab (P = .10) and 16-fold greater than that of placebo (P = .0001) at week 12 in the 240-mg cohort. Skin responses reached 85% suppression at week 12 in the 240-mg cohort and were maximal at week 18. The top doses of QGE031 consistently suppressed skin test responses among subjects but had a variable effect on allergen PC15 (2-fold to 500-fold change). QGE031 was well tolerated.

CONCLUSION:

QGE031 has greater efficacy than omalizumab on inhaled and skin allergen responses in patients with mild allergic asthma. These data support the clinical development of QGE031 as a treatment of asthma.

KEYWORDS:

Asthma management; IgE; QGE031; allergy; biologics; immunology; ligelizumab; mAb

PMID:
27185571
DOI:
10.1016/j.jaci.2016.02.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center